Generation of a human induced pluripotent stem cell line, YCMi002-A, from a Factor VII deficiency patient carrying F7...

Area of Science:

• Biomedical Research
• Genetics
• Hematology

Background:

• Factor VII (FVII) deficiency is a rare bleeding disorder caused by mutations in the FVII gene.
• Clinical manifestations range from mild symptoms to severe, life-threatening hemorrhages, including cerebral hemorrhage.
• Understanding the genotype-phenotype correlation is crucial for managing FVII deficiency.

Purpose of the Study:

• To generate and characterize a novel induced pluripotent stem cell (iPSC) line from a patient with Factor VII deficiency.
• To investigate the genetic mutations underlying the patient's FVII deficiency.
• To provide a cellular model for studying the impact of these mutations on FVII function and disease pathology.

Main Methods:

• Fibroblasts were obtained from a patient diagnosed with Factor VII deficiency.
• Reprogramming techniques were employed to generate induced pluripotent stem cells (iPSCs) from patient-derived fibroblasts.
• Genetic sequencing was performed to identify and confirm the mutations in the generated iPSC line.

Main Results:

• A novel iPSC line, designated YCMi002-A, was successfully established from FVII deficiency patient fibroblasts.
• YCMi002-A cells harbor compound heterozygous mutations in the FVII gene: a known mutation (c.345C>A; p.C115X) and a novel mutation (c.1276C>T; p.Q426X).
• The characterization confirmed the genetic makeup of the iPSC line relevant to FVII deficiency.

Conclusions:

• The YCMi002-A iPSC line represents a valuable new resource for Factor VII deficiency research.
• This cell line can facilitate the investigation of genotype-phenotype relationships in FVII deficiency.
• Further studies using YCMi002-A may elucidate the specific roles of the identified compound heterozygous mutations in disease severity.